Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serious Infections Prevalent in ANCA-Associated Vasculitis

By LabMedica International staff writers
Posted on 08 Apr 2021
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are among the rheumatic diseases with the highest mortality and morbidity, due to their major multi-organ involvement (lungs, kidneys) and their relapsing nature requiring aggressive immunosuppressive treatment.

Serious infections (SI) are common in patients with ANCA-AAV) like granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). More...
Real-life data regarding their incidence and predisposing factors, after the introduction of B cell depleting agents, are limited while data quantifying the risk per treatment modality and year of the disease are missing.

Clinical Immunologists at the Hippokration General Hospital (Athens, Greece) and their colleagues conducted a multicenter, observational, retrospective study of patients with AAV followed in three referral centers in the Athens. The study included 162 patients with GPA (63%) and MPA (37%), males 51.9%, mean age 60.9 years, ΑΝCA+ 86%, and generalized disease 80%. During follow-up (891.2 patient-years, mean 5.4 years), 67 serious infections (SI) were recorded in 50 patients at an incidence rate of 7.5 /100 patient-years.

The team collected from each participant age, sex, date of diagnosis, diseases severity, disease activity at baseline (Birmingham Vasculitis Activity Score), ANCA serology, organ involvement, relapses, renal function [estimated glomerular filtration rate (eGFR) by CKD-EPI formula] during first induction of remission course) and treatment patterns (treatment types and duration for each treatment, both for induction and maintenance of remission as well as initial glucocorticoids (GC) dose at diagnosis). SI was defined those needing hospitalization or intravenous antibiotics as well as opportunistic infections. Given the high frequency of herpes zoster (HZ) in AAV population and the accompanying morbidity of this infection, all cases of HZ were considered as SI irrespective of hospitalization need.

The scientists found that the incidence of SI among patients undergoing induction treatment with cyclophosphamide was 19.34/100 patient-years compared with 11.34/100 for those whose induction regimen was with rituximab, for an incidence rate ratio for cyclophosphamide of 4.24. Patients with ANCA-associated vasculitides granulomatosis with polyangiitis and microscopic polyangiitis continued to have significant morbidity and mortality despite improvements in treatment, such as the wider use of rituximab, and the incidence of serious infections remained high.

Mean baseline estimated glomerular filtration rate (GFR) was 59.1 mL/min, and in almost a quarter of patients, the baseline GFR was below 30 mL/min. Renal replacement therapy and/or plasma exchange was needed at baseline for 6.2%. Site of infection was the respiratory tract in 45% of patients, and the gastrointestinal tract and urinary tract in 9% each. The infection was herpes zoster in 24% and bacteremia in 9%.

The authors concluded that in this real-life study of patients with AAV, the SI incidence was higher during cyclophosphamide compared to rituximab (RTX) induction while there was no difference between RTX and other agents used for maintenance therapy. Higher disease activity at baseline and need for plasmapheresis and/or dialysis were independent factors associated with an SI. The study was published on March 20, 2021 in the journal Arthritis Research & Therapy.

Related Links:
Hippokration General Hospital


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated PCR Setup
ESTREAM
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.